Previous close | 2.0100 |
Open | 1.8800 |
Bid | 0.1000 |
Ask | 5.0000 |
Strike | 45.00 |
Expiry date | 2024-06-21 |
Day's range | 1.8800 - 2.0100 |
Contract range | N/A |
Volume | |
Open interest | 906 |
Chief Scientific Officer Stephen Betz of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) sold 3,000 shares of the company on June 10, 2024, according to a recent SEC Filing.
SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on June 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 158,000 shares of its common stock to nine new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements ma
Crinetics unveiled "stunning" results from a study of a major drug. Crinetics stock rose Monday.